DiaMedica Therapeutics Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
DiaMedica Therapeutics Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2018 to Q3 2024.
  • DiaMedica Therapeutics Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $565K, a 32.9% increase year-over-year.
  • DiaMedica Therapeutics Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $1.95M, a 19.2% increase year-over-year.
  • DiaMedica Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2023 was $1.68M, a 12.1% increase from 2022.
  • DiaMedica Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2022 was $1.5M, a 3.59% decline from 2021.
  • DiaMedica Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2021 was $1.56M, a 15.5% decline from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $1.95M $565K +$140K +32.9% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 $1.81M $443K +$63K +16.6% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 $1.75M $488K +$66K +15.6% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $1.68M $456K +$45K +10.9% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-19
Q3 2023 $1.64M $425K +$7K +1.68% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 $1.63M $380K +$15K +4.11% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 $1.62M $422K +$114K +37% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $1.5M $411K +$113K +37.9% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-19
Q3 2022 $1.39M $418K +$115K +38% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 $1.27M $365K -$81K -18.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 $1.36M $308K -$203K -39.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 $1.56M $298K -$208K -41.1% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-28
Q3 2021 $1.77M $303K -$205K -40.4% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 $1.97M $446K +$10K +2.29% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 $1.96M $511K +$118K +30% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 $1.84M $506K +$105K +26.2% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-14
Q3 2020 $1.74M $508K +$57K +12.6% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 $1.68M $436K +$254K +140% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-11
Q1 2020 $1.43M $393K +$263K +202% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q4 2019 $1.16M $401K +$336K +517% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-10
Q3 2019 $828K $451K +$341K +310% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-04
Q2 2019 $487K $182K -$110K -37.7% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-11
Q1 2019 $597K $130K -$23K -15% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-13
Q4 2018 $620K $65K Oct 1, 2018 Dec 31, 2018 10-K 2020-03-23
Q3 2018 $110K Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-13
Q2 2018 $292K Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-13
Q1 2018 $153K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.